Literature DB >> 15970587

The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1.

Nicolas Sluis-Cremer1, Dominique Arion, Urvi Parikh, Dianna Koontz, Raymond F Schinazi, John W Mellors, Michael A Parniak.   

Abstract

The mechanism of human immunodeficiency virus (HIV) 1 resistance to 3'-azido-3'-deoxythymidine (AZT) involves reverse transcriptase (RT)-catalyzed phosphorolytic excision of the chain-terminating AZT-5'-monophosphate (AZTMP). Primers terminated with AZTMP are generally better substrates for this reaction than those terminated with 2',3'-dideoxynucleoside-5'-monophosphate (2',3'-ddNMP) analogs that lack a 3'-azido moiety. This led to the hypothesis that the 3'-azido group is a major structural determinant for maintaining the primer terminus in the appropriate site for phosphorolytic excision of AZTMP by AZT-resistant (AZT(R)) RT. To test this hypothesis, we evaluated the incorporation, phosphorolytic excision, and antiviral activity of a panel of 3'-azido-2',3'-ddN including 3'-azido-2',3'-ddA (AZddA), 3'-azido-2',3'-ddC (AZddC), 3'-azido-2',3'-ddG (AZddG), AZT, and 3'-azido-2',3'-ddU (AZddU). The results indicate that mutations correlated with resistance to AZT (D67N/K70R/T215F/K219Q) confer resistance to the 3'-azidopyrimidine nucleosides (AZddC, AZT, and AZddU) but not to the 3'-azidopurine nucleosides (AZddA and AZddG). The data suggest that the presence of a 3'-azido group on the 3'-terminal nucleotide of the primer does not confer increased phosphorolytic excision by AZT(R) RT for all 3'-azido-ddNMP analogs. Thus, the 3'-azido group cannot be the only structural determinant important for the enhanced phosphorolytic excision of AZTMP associated with HIV resistance to AZT. Other structural components, such as the base, must play a role in defining the specificity of the excision phenotype arising from AZT resistance mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970587     DOI: 10.1074/jbc.M503166200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

Review 2.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

3.  Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

Authors:  Hong-Wang Zhang; Mervi Detorio; Brian D Herman; Sarah Solomon; Leda Bassit; James H Nettles; Aleksandr Obikhod; Si-Jia Tao; John W Mellors; Nicolas Sluis-Cremer; Steven J Coats; Raymond F Schinazi
Journal:  Eur J Med Chem       Date:  2011-05-30       Impact factor: 6.514

4.  The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.

Authors:  Jeffrey D Meteer; Dianna Koontz; Ghazia Asif; Hong-wang Zhang; Mervi Detorio; Sarah Solomon; Steven J Coats; Nicolas Sluis-Cremer; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

5.  Nucleotide Sugar Pucker Preference Mitigates Excision by HIV-1 RT.

Authors:  Ken Yamada; Alexander S Wahba; Jean A Bernatchez; Tatiana Ilina; Saúl Martínez-Montero; Maryam Habibian; Glen F Deleavey; Matthias Götte; Michael A Parniak; Masad J Damha
Journal:  ACS Chem Biol       Date:  2015-07-22       Impact factor: 5.100

6.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

7.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

8.  The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro.

Authors:  Jinwoo Ahn; In-Ja L Byeon; Sanjeewa Dharmasena; Kelly Huber; Jason Concel; Angela M Gronenborn; Nicolas Sluis-Cremer
Journal:  Retrovirology       Date:  2010-05-07       Impact factor: 4.602

9.  Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.

Authors:  Hong-Wang Zhang; Steven J Coats; Lavanya Bondada; Franck Amblard; Mervi Detorio; Ghazia Asif; Emilie Fromentin; Sarah Solomon; Aleksandr Obikhod; Tony Whitaker; Nicolas Sluis-Cremer; John W Mellors; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2009-11-13       Impact factor: 2.823

10.  Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.

Authors:  Shannon Zelina; Chih-Wei Sheen; Jessica Radzio; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.